Exposure-Response-Based Product Profile-Driven Clinical Utility Index for Ipatasertib Dose Selection in Prostate Cancer.

CPT Pharmacometrics Syst Pharmacol · 2019 · PMC6482275 · PMID 30762302

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

a slight trendno p-value reported

The E‐R analysis of the rPFS HR did not demonstrate a statistically significant ( P < 0.05) association between ipatasertib exposure (AUC ss,event ) and rPFS HR, with a slight trend of higher exposure leading to a lower rPFS HR ( Table S1 ).

also in 4,078 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.